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Abstract
Introduction: Hepatocyte growth factor (HGF) is a potent proangiogenic molecule that induces neovascularization.
The HGF antagonist, NK4, competitively antagonizes HGF binding to its receptor. In the present study, we
determined the inhibitory effect of NK4 in a rheumatoid arthritis (RA) model using SKG mice.
Methods: Arthritis was induced in SKG mice by a single intraperitoneal injection of b-glucan. Recombinant
adenovirus containing NK4 cDNA (AdCMV.NK4) was also injected intravenously at the time of or 1 month after
b-glucan injection. Ankle bone destruction was examined radiographically. The histopathologic features of joints
were examined using hematoxylin and eosin and immunohistochemical staining. Enzyme-linked immunosorbent
assays were used to determine the serum levels of HGF, interferon g (IFN-g, interleukin 4 (IL-4) and IL-17 production
by CD4+ T cells stimulated with allogeneic spleen cells.
Results: The intravenous injection of AdCMV.NK4 into SKG mice suppressed the progression of b-glucan-induced
arthritis. Bone destruction was also inhibited by NK4 treatment. The histopathologic findings of the ankles revealed
that angiogenesis, inflammatory cytokines and RANKL expression in synovial tissues were significantly inhibited by
NK4 treatment. Recombinant NK4 (rNK4) proteins inhibited IFN-g, IL-4 and IL-17 production by CD4+ T cells
stimulated with allogeneic spleen cells.
Conclusions: These results indicate that NK4 inhibits arthritis by inhibition of angiogenesis and inflammatory
cytokine production by CD4+ T cells. Therefore, molecular targeting of angiogenic inducers by NK4 can potentially
be used as a novel therapeutic approach for the treatment of RA.
Keywords: Adenovirus, Angiogenesis, Hepatocyte growth factor, Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease which causes progressive deformity and destruction
of the joints [1]. RA is characterized by aggressive synovial
expansion and invasion and subsequent destruction of the
underlying cartilage and bone. Synovial expansion is
dependent on an adequate blood supply for nutrients and
oxygen. New blood vessel formation (angiogenesis) is
therefore critically important for the delivery of oxygen,
nutrients and inflammatory cells to the lesions of RA [2,3].
There is mounting evidence that angiogenic inducers,
such as vascular endothelial growth factor (VEGF), play a
pivotal role in RA [4-6]. The intravenous administration
of adenovirus expressing sFlt-1, the secreted form of the
extracellular domain of the Flt-1 VEGF receptor, in a col-
lagen-induced arthritis (CIA) model results in blocking of
VEGF receptor signaling and a reduction in joint swelling
[7].
Hepatocyte growth factor (HGF) has angiogenic activ-
ity for vascular endothelial cells [8]. HGF has a role in
the dynamic construction and reconstruction of normal
tissues during organogenesis and tissue regeneration [9];
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however, tumor cells utilize the biological actions of
HGF for dissociative, invasive and metastatic behavior
[10]. The abrogation of HGF receptor (c-Met)-mediated
signaling events appears to be a highly promising strat-
egy for the prevention of tumor metastasis [11]. NK4
has been isolated as a competitive antagonist for HGF
and the c-Met receptor [12], and subsequent studies
have shown that NK4 also inhibits the angiogenic
response induced by basic fibroblast growth factor
(bFGF) and VEGF [13].
In the present study, we utilized adenovirus expressing
the NK4 gene, which has previously been demonstrated
to suppress tumor growth and vascularization in mice
[14]. Our data demonstrate that adenoviral delivery of
NK4 gene significantly suppresses disease activity in a
model of RA in SKG mice.
Materials and methods
Mice
Female SKG mice [15-17], 7 to 8 weeks old, were pur-
chased from CLEA Japan (Tokyo, Japan) and maintained
under specific pathogen-free conditions in the animal
facility of the Hyogo College of Medicine (Nishinomiya,
Hyogo, Japan). Female C57BL/6 (B6) mice, 8 to 12 weeks
old, were purchased from the Shizuoka Laboratory Animal
Center (Shizuoka, Japan). Animal experiments were con-
ducted in accordance with the guidelines of the National
Institutes of Health (Bethesda, MD, USA), as specified by
the animal care policy of Hyogo College of Medicine. All
of the experimental procedures were reviewed and
approved by the Animal Care and Use Committee of
Hyogo College of Medicine.
Clinical assessment of SKG arthritis
Arthritis was induced by a single intraperitoneal injec-
tion of the b-glucan laminarin (45 mg). Joint swelling
was monitored by inspection and scored as follows: 0,
no swelling; 0.1, swelling of one toe joint; 0.5, mild
ankle swelling; and 1.0, severe ankle swelling. The scores
for all toes and ankles were totaled for each mouse. The
ankle volume was measured with a water replacement
plethysmometer (Unicom Japan, Tokyo, Japan).
Preparation and measurement of NK4
AdCMV.NK4 and AdCMV.LacZ are structurally similar
replication-deficient recombinant adenovirus type 5
(Ad5)-based vectors with E1 and E3 deletions in which
the NK4 gene and LacZ transgene, respectively, are
under transcriptional control of the cytomegalovirus
(CMV) immediate-early enhancer and promoter. The
recombinant virus vectors were grown in HEK-293 cells
and twice purified by CsCl gradient centrifugation, and
titers were determined by serial dilution end point assay.
All vectors were free of replication-competent
adenovirus [18]. NK4 in serum was determined using an
enzyme-linked immunosorbent assay (ELISA) kit for
human HGF (Funakoshi Co, Tokyo, Japan). All work
was performed in accordance with an approved protocol
from the Institutional Biosafety Committee of Hyogo
College of Medicine.
Histopathology and immunohistochemistry
Joints were fixed in 10% formalin, decalcified using 10%
ethylenediaminetetraacetic acid in phosphate-buffered
saline (PBS) for 3 days, embedded in paraffin, sectioned
and stained with hematoxylin and eosin. Microscopic
examinations of the joints were conducted with subjec-
tive grading of inflammatory cell infiltration, synovial
hyperplasia and cartilage and bone destruction. Joint
grading was as follows [19]: normal, mild (minimum
inflammatory cell infiltration and synovial hyperplasia
with some cartilage loss), moderate (more extensive
inflammatory cell infiltration and synovial hyperplasia
with considerable bone erosion) and severe (complete
destruction of joint architecture). All analyses were per-
formed in a blinded fashion by an observer who was
unaware of the clinical status of the animal. For immu-
nohistochemical staining, cryostat sections of joints were
fixed in cold acetone for 10 min, washed in PBS and
depleted of endogenous peroxidase by treatment with
0.3% H2O2 in absolute methanol for 15 min. After
blocking nonspecific binding with 10% normal rabbit
serum in PBS for 30 min, the sections were incubated
with anti-mouse interleukin 6 antibody (IL-6 Ab; goat
immunoglobulin G (IgG)), anti-mouse tumor necrosis
factor a (TNF-a) Ab (goat IgG), anti-mouse CD31 Ab
(goat IgG), anti-RANKL (anti-receptor activator of
nuclear factor B ligand) Ab (goat IgG), anti-mouse IL-
17 Ab (goat IgG; all from Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-mouse IL-1 Ab (goat IgG;
R&D Systems, Minneapolis, MN, USA), anti-mouse HGF
Ab (rabbit IgG) or anti-mouse c-Met Ab (rabbit IgG) at
appropriate dilutions for 1 h at room temperature,
washed, incubated with biotinylated goat anti-rabbit IgG,
washed again and incubated with avidin-biotinylated
horseradish peroxidase complex (ABC) and 3,3’-diamino-
benzidine tetrahydrochloride (DAB) (VECTASTAIN
Elite ABC Kit; Vector Laboratories, Burlingame, CA,
USA) and counterstained with Mayer’s hematoxylin.
MH7A cells and synovial tissue specimens isolated from
patients with RA and osteoarthritis (OA) at the time of
arthroscopic biopsy or total joint replacement were
stained as reported previously [20]. Briefly, synovial tis-
sues were stained with anti-human HGF Ab (rabbit IgG)
or anti-human c-Met Ab (rabbit IgG), washed, incubated
with biotinylated goat anti-rabbit IgG, washed again,
incubated with ABC and DAB and counterstained with
Mayer’s hematoxylin. All patients gave their informed
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consent to participate, and the Institutional Medical
Ethics Committee approved the study protocol.
Mixed lymphocyte reaction and in vitro cytokine
production
The mixed lymphocyte reaction was performed as
described previously [21,22]. Briefly, CD4+ T cells and
CD11c+ dendritic cells (DCs) were purified from spleens
using immunomagnetic beads (Miltenyi Biotec, Auburn,
CA, USA). The purity of the CD4+ and CD11c+ popula-
tions was greater than 95% and more than 90%, respec-
tively. DCs from C57BL/6 mice (H-2b; 1 × 106 cells/ml/
well) were incubated in the presence or absence of HGF
or NK4 for 24 h. After thrice washing with Hanks’
balanced salt solution (HBSS), DCs were irradiated
(20 Gy) and cocultured with CD4+ T cells from SKG mice
(H-2d; 4 × 106 cells/ml/well) in 24-well flat-bottomed
plates (Falcon Labware, Lincoln Park, NJ, USA). After
72 h, viable cells were harvested, and, after thrice washing
with HBSS, the cells (1 × 105 cells/200 μl/well) were sti-
mulated in 96-well flat-bottomed plates (Falcon Labware)
coated with 5 μg/ml anti-mouse CD3 mAb. After 48 h,
interferon g (IFN)-g, IL-4 and IL-17 concentrations in the
culture supernatants were measured by ELISA using anti-
mouse IFN-g, IL-4 and IL-17 mAbs, respectively (Gen-
zyme, Cambridge, MA, USA), according to the manufac-
turer’s protocol.
Serum HGF ELISA
The serum HGF levels in SKG mice were measured by
ELISA using anti-mouse HGF mAb (R&D Systems)
according to the manufacturer’s protocol.
Bone X-ray
The ankles were examined radiographically after the
mice were killed by CO2 inhalation on day 60. X-ray
images of the ankles were obtained with an X-ray appa-
ratus (μFX-1000; FUJIFILM, Tokyo, Japan) using the fol-
lowing settings: 100 kV, 40 μA and 7-s exposure time.
Statistics
Student’s t-test was used for statistical analysis.
Results
AdCMV.NK4 induces NK4 proteins in SKG mice in vivo
To verify the in vivo production of NK4 protein after
AdCMV.NK4 injection, AdCMV.NK4 (1 × 109 plaque-
forming units (pfu)) was injected intravenously into SKG
mice. We observed significantly elevated levels of NK4
protein in the blood 1 day after injection (Figure 1A).
Systemically administered adenoviruses are scavenged by
the reticuloendothelial system (primarily in the liver)
[23]. We also observed the expression of NK4 protein in
the liver by immunohistochemistry 1 day after injection
(Figure 1B).
HGF and c-Met expression in the synovia of SKG mice
and RA patients
To examine whether the HGF/c-Met pathway is
involved in the pathogenesis of RA, we first determined
the expression of HGF and c-Met in the synovia of SKG
mice. In SKG mice, joint swelling began to develop in a
few digits approximately 1 month after b-glucan injec-
tion, subsequently progressing to other digits and to lar-
ger joints (wrists and ankles) in a symmetric fashion.
Immunohistochemical staining of synovial tissues 2
months after b-glucan injection revealed high expression
of c-Met in the synovial lining and vascular cells. HGF
was also expressed in the synovial lining and fibroblastic
cells (Figure 2A). The serum levels of HGF in arthritis-
induced SKG mice were higher than in untreated SKG
mice (Figure 2B). We next examined the expression of
c-Met and HGF in the synovium. c-Met expression in
mononuclear cells, blood vessels and synovial lining
cells of RA patients was higher than in OA patients.
HGF was expressed in the synovial lining and fibroblas-
tic cells of RA and OA synovial tissues (Figure 2C).
AdCMV.NK4 reduces clinical score and joint swelling in
SKG mice
To determine whether NK4 inhibited joint swelling,
AdCMV.NK4 (1 × 109 pfu), or AdCMV.LacZ (1 × 109 pfu)
as a control, was administered intravenously to the mice
from the time of b-glucan injection. Joint swelling of the
AdCMV.LacZ-treated SKG mice began on day 32 after
b-glucan injection and progressed significantly on day 75.
In contrast, mice that received AdCMV.NK4 had less joint
swelling as determined by the clinical score (Figure 3A)
and ankle volume (Figure 3B) 60 days following b-glucan
injection. In clinical situations, gene therapy is more likely
to be used therapeutically than to prevent disease. To
determine the therapeutic effectiveness of this treatment
on arthritis, we introduced AdCMV.NK4 (1 × 109 pfu)
into SKG mice 1 month after b-glucan injection. SKG
mice that received AdCMV.NK4 had less joint swelling
than control mice that received AdCMV.LacZ 60 days fol-
lowing b-glucan injection (Figure 3C).
AdCMV.NK4 reduces histopathologic changes in SKG mice
The histopathologic features of swollen joints in
AdCMV.LacZ-treated SKG mice, as shown by hematoxy-
lin and eosin staining, included vigorous proliferation of
synovial cells and infiltration of synovial tissues by mono-
nuclear cells and neutrophils, which has been observed in
human RA [1]. In contrast, these pathologic changes
were significantly inhibited in NK4-treated SKG mice.
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X-ray examination of the ankle joints 60 days following
b-glucan injection of AdCMV.LacZ-treated SKG mice
revealed erosion of the cartilage and subchondral bone,
whereas these changes were inhibited in NK4-treated
SKG mice (Figure 4).
AdCMV.NK4 reduces inflammatory cell infiltration, as well
as cytokine and RANKL expression, in synovial tissue
Immunohistochemical staining of synovial tissues from
AdCMV.LacZ-treated SKG mice revealed high expres-
sion of IL-1, IL-6 and TNF-a. In contrast, AdCMV.
Figure 1 AdCMV.NK4 induces NK4 protein in SKG mice. SKG mice were injected intravenously with AdCMV.NK4 (1 × 109 plaque-forming units
(pfu)) into the tail vein. One day after injection, serum and liver were obtained and NK4 protein levels in the serum (A) and NK4 protein expression in
the liver (B) were measured by hepatocyte growth factor (HGF) enzyme-linked immunosorbent assay (ELISA) or immunohistochemistry, respectively.
Data in (A) are represented as the means ± SD (n = 6). The arrows in (B) represent NK4 protein expression in hepatocytes. Original magnification, ×100.
Figure 2 Serum levels of hepatocyte growth factor (HGF) and HGF and c-Met expression in the synovium. (A) The histologic feature of
swollen joints 60 days after induction of arthritis in SKG mice expressed HGF and c-Met in the synovium. Original magnification, ×200; inset,
×400. (B) The serum levels of HGF in b-glucan-injected SKG mice (60 days after induction) were higher than in untreated SKG mice. Data are
represented as the means ± SD (n = 4). *P = 0.06. (C) The histologic feature of joints in RA patients expressed HGF and c-Met in the synovium
(BV, blood vessel; F, fibroblastic cell; M, mononuclear cell; OA, osteoarthritis; RA, rheumatoid arthritis; SL, synovial lining cell layer). Original
magnification, ×100; inset, ×400. We examined the histologic features of joints in osteoarthritis patients as a control.
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NK4-treated SKG mice did not express these cytokines
AdCMV.NK4 treatment also inhibited type 17 T-helper
(Th17) cell infiltration and RANKL expression in the
synovial tissues (Figure 5).
Recombinant NK4 inhibits interferon g, interleukin 4 and
interleukin 17 production by CD4+ T cells in vitro
We examined the effect of recombinant NK4 (rNK4) on
the production of IFN-g, IL-4 and IL-17 by CD4+ T cells
stimulated with allogeneic DCs. CD11c+ DCs from
C57BL/6 mice were preincubated in the presence or
absence of HGF or NK4 for 24 h. CD4+ T cells from
SKG mice were cultured with irradiated CD11c+ DCs,
and IFN-g, IL-4 and IL-17 production in culture superna-
tants was measured by ELISA. Preincubation of rNK4
and HGF inhibited IFN-g, IL-4 and IL-17 production by
CD4+ T cells (Figure 6).
Discussion
We have demonstrated that the HGF antagonist NK4
significantly suppresses arthritis in a SKG mouse model,
as demonstrated by the ankle volume and arthritis
score. It has been reported that HGF is expressed in
synovial tissues and that vascular endothelial cells
Figure 3 AdCMV.NK4 reduces clinical score and ankle swelling. Arthritis was induced by a single intraperitoneal injection of the b-glucan
laminarin (45 mg). AdCMV.NK4 (1 × 109 plaque-forming units (pfu); n = 8; filled squares) or AdCMV.LacZ (1 × 109 pfu; n =8; filled diamonds) was
administered intravenously at the time of laminarin injection. (A) Changes in arthritis scores were monitored over the course of 60 days. (B) The ankle
swelling in mice treated with AdCMV.NK4 (1 × 109 pfu) or AdCMV.LacZ was examined on day 60 after induction of arthritis. (C) To determine the
therapeutic effectiveness of this treatment on arthritis, we introduced AdCMV.NK4 (1 × 109 pfu; n = 8) or AdCMV.LacZ (1 × 109 pfu; n = 8) into SKG
mice 1 month after b-glucan injection, and the ankle swelling was examined on day 60 after induction of arthritis (C). Arthritis scores were monitored
by inspection as follows: 0, no swelling; 0.1, swelling of one toe joint; 0.5, mild paw swelling; and 1.0, severe paw swelling. The results are expressed as
the means ± SD. *P < 0.05 vs SKG mice given AdCMV.NK4. Representative data of two separate experiments are shown.
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express c-Met in patients with RA [24]. Synovial fluid
HGF in patients with RA is produced by synovial cells
and is related to disease activity [25]. We also demon-
strated that HGF is expressed in synovial lining cells,
and c-Met is strongly expressed in mononuclear, vascu-
lar endothelial and synovial lining cells of RA patients.
These results suggest that NK4 inhibits angiogenesis
induced by HGF-c-Met signaling in synovial tissues of
patients with RA.
NK4 is a proteolytic fragment of HGF, consisting of an
N-terminal hairpin domain and four kringle domains of
the a chain of HGF [12]. The NK4 fragment appears to be
generated by mast cell and neutrophil peptidases under
physiologic and pathologic conditions such as inflamma-
tion and cancer, thus regulating angiogenesis [26]. In addi-
tion to antagonizing HGF by competitively binding to
c-Met, NK4 inhibits the angiogenic responses of endothe-
lial cells induced by bFGF and VEGF [13], suggesting that
new binding molecules of NK4 other than c-Met may
exist, such as perlecan, the major extracellular heparan
sulfate proteoglycans associated with blood vessels as pre-
viously reported [27].
The systemic administration of AdCMV.NK4 induced
the production of significant NK4 protein in the blood
and liver 1 day after administration. Adenoviral vectors
have particular advantages for use as in vivo gene transfer
vehicles, including a broad host range, the ability to infect
both dividing and nondividing cells and the ease of high-
titer purification [28]. Studies using adenovirus encoding
for inflammatory cytokines or their receptors, such as
TNF receptor p55, IL-4 and IL-10 in CIA have been
reported [29-31]. Administration of adenovirus expressing
Figure 4 AdCMV.NK4 inhibits histopathologic changes. (A) The histologic features of swollen joints 60 days after induction of arthritis in LacZ-
treated SKG mice exhibited severe synovitis accompanying massive subsynovial infiltration of neutrophils, lymphocytes and macrophages with
villous proliferation of synoviocytes. These pathologic changes were significantly inhibited in NK4-treated SKG mice. Original magnification, ×100;
inset, ×400. (B) X-ray bone examination taken 60 days after induction of arthritis revealed severe destruction of ankle joints in LacZ-treated SKG
mice. These bone changes were inhibited in NK4-treated SKG mice. (C) The percentage of joints exhibiting mild (white bar), moderate (gray bar)
and severe (black bar) pathologic changes by AdCMV.NK4-treated SKG mice (n = 8) or AdCMV.LacZ-treated SKG mice (n = 8) 60 days after
induction of arthritis.
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Flt-1 was also able to suppress clinical scores, ankle swel-
ling and joint destruction [7]. sFlt-1 expression was
demonstrated in systemic and effecter regions, although
the expression was transient because of antibody
responses targeting the adenovirus and human transgene.
We also measured NK4 protein in serum by ELISA using
anti-human HGF antibody. In mice receiving 1 × 109 pfu
of Ad.CMV.NK4 via the tail vein, NK4 protein in serum
peaked at more than 1,300 pg/ml 24 h after transduction,
then gradually declined to 0 ng/ml 14 days after transduc-
tion (data not shown). These results suggest that short-
term blockage of angiogenesis in the early phase of arthritis
inhibits arthritis in SKG mice. To determine the therapeu-
tic effectiveness of this treatment on arthritis, we intro-
duced AdCMV.NK4 (1 × 109 pfu) into SKG mice 1 month
after b-glucan injection. SKG mice that received AdCMV.
NK4 had less joint swelling than control mice that received
AdCMV.LacZ 60 days following b-glucan injection.
Presentation of antigen by antigen-presenting cells
(APCs) to T cells initiates the differentiation of naïve Th
cells into effector T cells. The expression of costimulatory
molecules on APCs and the cytokine profile produced by
APCs play a critical role during the differentiation into
each T-cell phenotype, such as Th1, Th2 or regulatory T
(Treg) cells [32]. DCs are the most efficient and crucial
APCs [33]. Recent studies have reported the effect of HGF
on DC function [34,35]. Rutella et al. [35] reported that, in
in vitro experiments, HGF suppresses alloantigen-present-
ing capacity, modulates costimulatory molecule expression
and cytokine production of DCs and generates DCs that
induce Treg cells. Okunishi et al. [34] reported that HGF
potently suppresses antigen-presenting capacity and
Figure 5 AdCMV.NK4 inhibits inflammatory cell infiltration, as well as cytokine and RANKL expression, in the synovial tissues of SKG
mice. Immunohistochemistry of interleukin 1 (IL-1) (A), IL-6 (B), TNF-a (C), CD31 (D), IL-17 (E) and RANKL (receptor activator of nuclear factor
B ligand) (F). High-level expression of IL-1, IL-6, TNF-a, CD31, IL-17 and RANKL in the synovial tissues of LacZ-treated SKG mice was observed
(upper). In contrast, the expression was significantly inhibited in the synovial tissues of NK4-treated SKG mice (lower). Original
magnification, ×200.
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IL-12p70 production of DCs, thus inhibiting development
of Th1- and Th2-type immune responses induced by oval-
bumin. Okunishi et al. [36] also demonstrate that HGF
potently inhibits the development of CIA with augmenta-
tion of the Th2-type immune response and suppression of
IL-17 production. Because NK4 antagonizes HGF, it is
thought that NK4 inhibits immune responses induced by
HGF. In contrast, AdCMV.NK4 inhibited inflammatory
cytokine expression in synovial tissues of SKG mice. In
addition, rNK4 inhibited IFN-g, IL-4 and IL-17 production
from the CD4+ T cells stimulated with allogeneic spleen
cells. Although the precise mechanisms by which NK4
inhibits inflammatory responses are not clear, it is possible
that new binding molecules of NK4 on DCs may exert
these functions after binding to NK4.
Conclusions
Our results demonstrate that systemic administration of
AdCMV.NK4 inhibits synovial cell proliferation and inflam-
matory responses in the joints of SKG mice in a RA model.
We have also demonstrated that NK4 inhibits inflamma-
tory cytokine production by CD4+ T cells. The data indi-
cate the potential utility of NK4 in the treatment for RA.
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